Meeting
2019 Genitourinary Cancers Symposium
Real-world trends in first-line checkpoint inhibitor use (CPI) in advanced urothelial cell carcinoma (aUC).
Authors
Ravi Bharat Parikh
Abramson Cancer Center, Philadelphia, PA
Ravi Bharat Parikh , Matt D. Galsky , Shrujal S. Baxi , Blythe J.S. Adamson , Aaron Benjamin Cohen , Emily Feld , John Paul Christodouleas , Shimon Ben Boursi , Neal J. Meropol , Ronac Mamtani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 392)
DOI
10.1200/JCO.2019.37.7_suppl.392
Abstract #
392
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
First Author: Thomas Powles
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.
First Author: Fernando Cotait Maluf